Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
This comprehensive resource covers product change evaluation, postmarket surveillance, audit/inspection compliance, and various other laws and regulations pertaining to maintaining a product on the market.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Regulatory News | 27 October 2014 | By Louise Zornoza
This content is provided by RegLink News, publishers of e-weekly global regulatory news. RegLink offers a 30-day free trial and 15% discount on Global Update subscriptions to RAPS members.
The Australian government has announced that experts will review the Therapeutic Goods Administration’s (TGA) framework for the regulation of medicines and medical devices.
According to a 24 October 2014 announcement by Health Minister Peter Dutton and Assistant Minister for Health Fiona Nash, the review “will identify ways to assist medicine and medical device producers and suppliers struggling with complex and costly regulatory pathways.”
A Panel of three experts will examine TGA’s regulatory framework and consult with health professionals, industry, consumers and other stakeholders to identify areas of unnecessary, duplicative, or ineffective regulation that could be removed or streamlined. The Review Panel will consist of: the former Chair of the Pharmaceutical Benefits Advisory Committee, Emeritus Professor Lloyd Sansom; the former Chief Medical Officer at the Department of Health, Professor John Horvath; and the former Managing Director of Merck, Sharp & Dohme in Australia, Mr. Will Delaat.
(Announcement)
Tags: TGA, Australia